"The commercial launch of RAYOS further affirms our commitment to provide innovative therapeutic options to patients who suffer from arthritis, pain and inflammatory diseases and to the physicians who treat them," said
In July of this year, the
Specific results from CAPRA-2 demonstrated:
Results from CAPRA-2 were published online in Annals of the Rheumatic Diseases (doi:10.1136/annrheumdis-2011-201067) on
The safety of RAYOS was based on the evaluation of 375 RA patients in two controlled trials. Patients treated with RAYOS ranged in age from 20 to 80 years (median age 56 years). Patients were predominantly Caucasian and 85 percent were female.
Included in these safety results were data from the CAPRA-1 trial, a 12-week, double-blind, randomized controlled study that evaluated 288 RA patients. CAPRA-1 compared
The clinical trial experience did not raise any safety concerns beyond those already established for immediate-release prednisone.
Results from the CAPRA-1 12-week study and the 9-month open-label extension have been published in The Lancet and Annals of the Rheumatic Diseases, respectively.
RAYOS, known as LODOTRA® in
RAYOS utilizes SkyePharma's proprietary Geoclock™ technology under an exclusive license from SkyePharma.
Outside the U.S., LODOTRA is approved in 19 countries for the treatment of moderate to severe active RA when accompanied by morning stiffness. Horizon has granted commercialization rights for LODOTRA in
Important Safety Information
RAYOS® (prednisone) delayed-release tablets
Approved uses of RAYOS
RAYOS, a delayed-release form of prednisone, prevents the release of substances in the body that cause inflammation. RAYOS is approved to treat a broad range of diseases including RA, polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD). For a full list of RAYOS indications, please see full prescribing information at www.RAYOSrx.com.
RAYOS is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroids.
Important information about RAYOS
Do not use RAYOS if you are allergic to prednisone.
Long-term use of RAYOS can affect how your body responds to stress. Symptoms can include weight gain, severe fatigue, weak muscles and high blood sugar.
RAYOS can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had.
RAYOS can cause high blood pressure, salt and water retention and low blood potassium.
There is an increased risk of developing holes in the stomach or intestines if you have certain stomach and intestinal disorders.
Behavior and mood changes can occur, including intense excitement or happiness, sleeplessness, mood swings, personality changes or severe depression.
Long-term use of RAYOS can cause decreases in bone density.
RAYOS can cause cataracts, eye infections and glaucoma.
Do not receive a "live" vaccine while taking RAYOS. The vaccine may not work as well during this time and may not fully protect you from disease.
Taking RAYOS during the first trimester of pregnancy can harm an unborn baby.
Long-term use of RAYOS can slow growth and development in children.
The most common side effects with RAYOS are water retention, high blood sugar, high blood pressure, unusual behavior and mood changes, increased appetite and weight gain.
Please see full prescribing information for RAYOS at www.RAYOSrx.com.
This press release contains forward-looking statements, including statements regarding Horizon's commercialization plans for RAYOS and the timing for implementing those plans. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company's ability to commercialize products successfully, potential delays or changes in strategy for the commercial launch of RAYOS, whether physicians will prescribe and patients will use RAYOS and competition in the market for RAYOS. For a further description of these and other risks facing Horizon, please see the risk factors described in Horizon's filings with the
Todd N. SmithExecutive Vice President, Chief Commercial Officer Email Contact Kathy Galante Burns McClellan, Inc.212-213-0006 Email Contact
News Provided by Acquire Media